Vetenskapliga artiklar

LL-37 och kroniska sår

• Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O. (2014).Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: A randomized, placebo-controlled clinical trial. Wound Repair & Regenerat, 22(5):613-21.
• Rivas-Santiago B, Trujillo V, Montoya A, Gonzalez-Curiel I, Castaneda-Delgado J et al. (2012).Expression of antimicrobial peptides in diabetic foot ulcer. J Dermatol Sci, 65:19–26.
• Ramos R, Silva JP, Rodrigues AC, Costa R, Guardao L, Schmitt F et al. (2011).Wound healing activity of the human antimicrobial peptide LL-37. Peptides, 32:1469–76.
• Tokumaru S, Sayama K et al. (2005). Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol, 175(7):4662-8.
• Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T, Issbrucker K et al. (2003).An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest, 111(11):1665-72.
• Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. (2002). The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol, 169(7):3883-3891
• Dorschner RA1, Pestonjamasp VK, Tamakuwala S, Ohtake T, Rudisill J, Nizet V, Agerberth B, Gudmundsson GH,Gallo RL. (2001). Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol, 117(1):91-7.